This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck Cancer

This study has been completed.
Information provided by (Responsible Party):
Inovio Pharmaceuticals Identifier:
First received: September 12, 2005
Last updated: September 11, 2017
Last verified: September 2017
The purpose of the trial is to study the safety and efficacy of the Medpulser Electroporation System with bleomycin in the treatment of head and neck cancer.

Condition Intervention Phase
Head and Neck Cancer Device: Medpulser Electroporation with Bleomycin Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Study Using the Medpulser® Electroporation System to Treat Head and Neck Cancer

Resource links provided by NLM:

Further study details as provided by Inovio Pharmaceuticals:

Primary Outcome Measures:
  • To characterize local tumor recurrence through 8 months post-EPT/bleomycin treatment [ Time Frame: 8 Months ]

Secondary Outcome Measures:
  • To measure pharmacoeconomic factors (hospital costs, extent of medical interventions, medication use) in subjects treated by EPT/bleomycin [ Time Frame: 24 Months ]
  • To evaluate organ function and appearance using the Performance Status Scale (PSS) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck (EORTC QLQ - H&N 35) at 4 and 8 months following treatment [ Time Frame: 4 and 8 Months ]
  • To document the performance of the MedPulser® System during EPT/bleomycin treatment [ Time Frame: 8 Nonths ]
  • To monitor local and systemic adverse events through the Month 4 follow-up study visit [ Time Frame: 4 Months ]

Enrollment: 95
Study Start Date: January 2004
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Bleomycin
Bleomycin 4 USP Units/mL; intratumorally at dose of 0.25mL/cm^3
Device: Medpulser Electroporation with Bleomycin
The MedPulser device will be used in conjunction with injection of Bleomycin Sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area.

Detailed Description:
Electroporation therapy is a tumor-specific ablative treatment modality with the potential to manage local tumors without the potentially undesirable side effects of systemic chemotherapy agents or radiotherapy. Surgical resection of solid tumors often leaves subjects with significant organ dysfunction and/or permanent disfigurement requiring reconstructive surgery. In contrast, electroporation therapy may offer equivalent disease control to conventional surgery with lessened need for reconstructive surgery. Electroporation therapy may also provide economic benefits over conventional surgical and or radiation procedures through reduced operating theatre costs, hospital stays and post treatment interventions. The ability to shrink or eliminate local tumors with the MedPulser® System when used in conjunction with intralesional Bleomycin is an important new possible treatment for the conservative local management of SCCHN and provides a possible alternative treatment option to surgical excision in the management of cancer.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. The presence of primary oral cavity, primary pharyngeal, primary laryngeal, salivary gland, limited recurrent and second primary tumors must be confirmed by histological examination of a tissue sample (e.g., biopsy) obtained within 2 months of the subject receiving the study treatment.
  2. The length of the longest diameter of the study lesion must be < 5 cm and the calculated treatment volume (tumor volume plus a 0.5 cm margin around the tumor) for the study lesion [where treatment volume = 0.5 (a+1) (b+1)2 and where a = length of the longest diameter (cm), b = the next longest diameter perpendicular to "a" (cm)] must be < 60.0 cm3.
  3. Age: 18 years or older.
  4. Male or female.
  5. Men and women of childbearing potential must be using Investigator prescribed contraceptive methods while undergoing protocol related therapy.
  6. Baseline performance status: ECOG 0-2:

    • Grade 0: Fully active, able to carry on all pre-disease performance without restriction.
    • Grade 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.
    • Grade 2: Ambulatory and capable of all self-care, but unable to carry out any work activities. Up and about more than 50% of waking hours.
  7. Life expectancy of at least 6 months.
  8. Subjects must sign a written Informed Consent prior to receiving any study procedures or treatments.

Exclusion Criteria:

  1. Subjects with tumors suspected of involving a 50% or greater encasement of a blood vessel as measured by magnetic resonance imaging (MRI) or computed tomography (CT) scan.
  2. Subjects with tumors having bone invasion.
  3. Subjects with hypersensitivity to bleomycin.
  4. Subjects who have received or will exceed a total lifetime dose of bleomycin greater than 400 units.
  5. Subjects deemed unsuitable for general anesthesia.
  6. Subjects with a significant history of emphysema or pulmonary fibrosis.
  7. Subjects with indwelling cardiac pacemakers who cannot tolerate a period with pacemaker turned off.
  8. Subjects with a history of uncontrolled cardiac arrhythmia.
  9. Women who are pregnant, or are nursing. Women must have a negative pregnancy test (urine pregnancy tests are acceptable) within 7 days of study treatment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00198263

United States, California
Inovio Biomedical Corporation
San Diego, California, United States, 92121
Sponsors and Collaborators
Inovio Pharmaceuticals
Study Chair: Paul Goldfarb, MD Inovio Pharmaceuticals
  More Information

Responsible Party: Inovio Pharmaceuticals Identifier: NCT00198263     History of Changes
Other Study ID Numbers: EU-HNBE-2003
Study First Received: September 12, 2005
Last Updated: September 11, 2017

Keywords provided by Inovio Pharmaceuticals:
head and neck cancer
primary oral cavity, primary pharyngeal, primary laryngeal, salivary gland, limited recurrent and second primary tumors

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms by Site
Antibiotics, Antineoplastic
Antineoplastic Agents processed this record on September 19, 2017